Abstract

Dissecting mechanisms of fecal microbiota transplantation efficacy in disease

Trends Mol Med. 2024 Mar;30(3):209-222. doi: 10.1016/j.molmed.2023.12.005.Epub 2024 Jan 8.

 

Catherine M Andary 1Kait F Al 2John A Chmiel 2Shaeley Gibbons 2Brendan A Daisley 3Seema Nair Parvathy 4Saman Maleki Vareki 5Dawn M E Bowdish 6Michael S Silverman 7Jeremy P Burton 8

 
     

Author information

1Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada.

2Department of Microbiology and Immunology, Western University, London, Ontario, Canada; Canadian Centre for Human Microbiome and Probiotics Research, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada.

3Department of Molecular and Cellular Biology, University of Guelph, Guelph, Ontario, Canada.

4Division of Infectious Disease, St. Joseph's Health Care, London, Ontario, Canada.

5Lawson Health Research Institute, London, Ontario, Canada; Department of Oncology, Western University, London, Ontario, Canada; Department of Pathology and Laboratory Medicine, Western University, London, Ontario, Canada.

6Michael G. DeGroote School of Medicine, McMaster University, Hamilton, Ontario, Canada; McMaster Immunology Research Centre and the Firestone Institute for Respiratory Health, McMaster University, Hamilton, Ontario, Canada.

7Department of Microbiology and Immunology, Western University, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada; Division of Infectious Disease, St. Joseph's Health Care, London, Ontario, Canada.

8Department of Microbiology and Immunology, Western University, London, Ontario, Canada; Canadian Centre for Human Microbiome and Probiotics Research, London, Ontario, Canada; Lawson Health Research Institute, London, Ontario, Canada; Department of Surgery, Western University, London, Ontario, Canada. Electronic address: jeremy.burton@lawsonresearch.com.

Abstract

Fecal microbiota transplantation (FMT) has emerged as an alternative or adjunct experimental therapy for microbiome-associated diseases following its success in the treatment of recurrent Clostridioides difficile infections (rCDIs). However, the mechanisms of action involved remain relatively unknown. The term 'dysbiosis' has been used to describe microbial imbalances in relation to disease, but this traditional definition fails to consider the complex cross-feeding networks that define the stability of the microbiome. Emerging research transitions toward the targeted restoration of microbial functional networks in treating different diseases. In this review, we explore potential mechanisms responsible for the efficacy of FMT and future therapeutic applications, while revisiting definitions of 'dysbiosis' in favor of functional network restoration in rCDI, inflammatory bowel diseases (IBDs), metabolic diseases, and cancer.

© Copyright 2013-2024 GI Health Foundation. All rights reserved.
This site is maintained as an educational resource for US healthcare providers only. Use of this website is governed by the GIHF terms of use and privacy statement.